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a b s t r a c t
Treatment for most persistent viral infections consists of palliative drug options rather than curative
approaches. This is often because long-lasting viral DNA in infected cells is not affected by current antivirals,
providing a source for viral persistence and reactivation. Targeting latent viral DNA itself could therefore
provide a basis for novel curative strategies. DNA cleavage enzymes can be used to induce targeted
mutagenesis of speciﬁc genes, including those of exogenous viruses. Although initial in vitro and even
in vivo studies have been carried out using DNA cleavage enzymes targeting various viruses, many questions
still remain concerning the feasibility of these strategies as they transition into preclinical research. Here, we
review the most recent ﬁndings on DNA cleavage enzymes for human viral infections, consider the most
relevant animal models for several human viral infections, and address issues regarding safety and enzyme
delivery. Results from well-designed in vivo studies will ideally provide answers to the most urgent remaining
questions, and allow continued progress toward clinical application.
& 2014 Elsevier Inc. All rights reserved.
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General overview
Recent advances in our ability to cleave and modify DNA at a
desired locus have energized the ﬁeld of genome editing. Restriction
enzymes have served for years as the workhorses for recombinant
DNA manipulation in a vast array of molecular biology applications.
However, the short DNA recognition sequences of restriction
enzymes limit their use in whole genome editing, due to the high
frequency in which their recognition sites occur by chance within a
given genome. In the 1980s the ﬁrst member of the homing
endonuclease (HE) family of DNA endonucleases I-SceI was isolated
(Colleaux et al., 1986). HEs have much larger DNA recognition
sequences (12–40 bp) than restriction enzymes (Chevalier and
Stoddard, 2001; Belfort and Roberts, 1997), and thus the likelihood
of cleavage occurring at unwanted sites of the genome is much lower,
allowing HEs to be used as DNA-targeting enzymes in live cells
without lethal toxicity. Thus, the identiﬁcation of HEs introduced the
potential for using DNA cleavage enzymes to manipulate the genome
in living cells. In recent years, the ability to engineer the DNA
speciﬁcity of HEs has vastly increased their utility in genome editing
applications (Gao et al., 2010; Grizot et al., 2010; Baxter et al., 2012).
In parallel with the development of HEs, a number of other
artiﬁcial site-speciﬁc DNA cleavage enzymes have been developed
that can also be designed to target desired DNA loci, including the
zinc ﬁnger nucleases (ZFNs), transcription activator like effector
nucleases (TALENs), and the CRISPR/Cas9 system (Schiffer et al.,
2012; Stone et al., 2013; Gaj et al., 2013). The development of
multiple classes of targeted site-speciﬁc endonucleases that cleave
large DNA sequences with high speciﬁcity has expanded the scope
of genome manipulation technology to the point that it is now
possible to cleave DNA at almost any sequence, and this is aiding
new efforts towards previously impossible therapeutic strategies.
Much of the research being carried out in the ﬁeld of genome
editing is based on gene correction, in which an endonuclease is
used to introduce a site-speciﬁc DNA double strand break (DSB)
that is repaired via homologous recombination (HR) using a HR
donor template that corrects the faulty genomic locus. Targeted HR
may also be used to introduce a missing gene or foreign sequence
into a targeted locus. However, site-speciﬁc endonucleases can
also be utilized for gene disruption applications. In mammalian
cells, the predominant mechanism for DNA DSB repair is non-
homologous end-joining, which is error-prone. Through imprecise
repair that results in frame-shift mutations or the deletion of
essential DNA sequences, genes can be targeted for disruption.
This mechanism offers a possible strategy for targeting exogenous
DNA sequences present in cells that have been infected by viruses.
By speciﬁcally targeting viral DNA for disruption, host cells might
effectively be “cured” of viral infection.
In this review we will discuss recent advances in the ﬁeld of
genome engineering toward using sequence-speciﬁc DNA cleavage
enzymes to suppress or eliminate viral infections. Recent in vitro
data suggest that essential viral genes from viruses including
hepatitis B virus (HBV), human immunodeﬁciency virus (HIV),
human papilloma virus (HPV), human simplex virus (HSV), and
human T cell lymphotropic virus (HTLV) can be disrupted, which
can lead to disruption or elimination of viral replication. Further-
more, initial in vivo studies suggest that antiviral therapies using
DNA cleavage enzymes can also disrupt certain viruses in animal
models of infection. It is clear from these studies that further
research will need to be performed in increasingly realistic and
relevant animal models of viral disease. The implementation of
genome-directed antiviral therapies faces many hurdles, including
the efﬁciency of enzyme delivery, rates of off-target enzyme
cleavage activity, and the development of therapy-associated
toxicity. As the ﬁeld continues to move forward, both the current
limitations of existing animal models and the potential hurdles to
DNA cleavage enzyme therapy will need to be appropriately
addressed.
Current progress in targeting viral infections
In vitro results
Many laboratories have now tested engineered DNA cleavage
enzymes using informative in vitro models. The ﬁrst enzyme
designed to target integrated HIV provirus was a Cre
recombinase-based enzyme speciﬁc for the HIV long terminal
repeat (LTR), referred to as Tre-recombinase (Buchholz and
Hauber, 2011; Sarkar et al., 2007). The LTR is present on both ends
of the HIV genome, and by successfully targeting both LTR sites,
excision of the viral DNA can be achieved (Sarkar et al., 2007).
Tre-recombinase has demonstrated signiﬁcant activity toward LTR
sequences in both episomal and stable integrated reporter con-
structs, including proviral excision from chromosomal integration
sites in transfected cells (Mariyanna et al., 2012). The enzyme has
been packaged into a lentiviral self-inactivation vector, allowing
delivery to HIV-infected cells and antiviral activity in the absence
of cytopathic effects (Hauber et al., 2013). Unfortunately, Tre-
recombinase was created to recognize the LTR from a rare HIV
strain of subtype A chosen for its sequence similarity to the wild-
type loxP sequence, which is not present in most HIV strains and
complicates broader application for other HIV strains.
The ﬁrst efforts targeting integrated provirus with a non-
recombinase DNA cleavage enzyme was a proof-of-principle study
that achieved HE-induced gene disruption of an integrated lenti-
viral reporter provirus in which the wild-type recognition site for
the HE Y2 I-AniI was inserted into a GFP open reading frame
(Aubert et al., 2011). Treatment with the enzyme resulted in a loss
of GFP ﬂuorescence due to misrepair of the cleaved target site.
Although these results are promising, they were obtained by
targeting a wild-type HE recognition sequence rather than a viral
sequence. More recently, engineered ZFNs targeting HIV proviral
DNA have been utilized to target and cleave the HIV LTR sequences
in latently infected cells as well as in HIV-infected human primary
cells, in vitro (Qu et al., 2013). These ZFNs, like Tre-recombinase,
were capable of excising the integrated provirus. In a similar study,
therapeutic ZFNs directed toward the LTR of HTLV-1 resulted in
disruption of LTR promoter activity and removal of the proviral
genome from infected cells (Tanaka et al., 2013). These ZFNs also
caused a drop in cell proliferation and resulted in DNA double
strand break-induced apoptosis. Comparable outcomes have been
achieved by targeting the HIV LTR with the CRISPR/Cas9 system in
infected cell lines (Ebina et al., 2013). Despite these advances,
targeting the LTR as a therapeutic strategy may have drawbacks,
since simultaneous cleavage of both LTR binding sites will be
needed for provirus excision. Additionally, the LTR does not
include coding sequences but instead functions as a promoter
region, so that the introduction of mutations within the LTR may
not be optimally detrimental to viral ﬁtness.
DNA cleavage enzymes can also target viruses with persistent
episomal forms. In targeting HPV, Mino et al. fused a staphylo-
coccal nuclease to an engineered zinc ﬁnger protein to cleave
episomal genomes, which inhibited HPV-18 DNA replication in a
cell culture model (Mino et al., 2013). Likewise, ZFNs and TALENs
have been used to induce mutations in HBV genomic sequences,
which exist in hepatocytes in an episomal covalently closed
circular (cccDNA) form. First, ZFNs were used to target a plasmid
containing HBV sequences resulting in a decrease in viral replica-
tive intermediates in transfected cells (Cradick et al., 2010). Later,
TALENs targeted to conserved regions in different HBV genotypes
showed disruption of the target site and knock down of viral
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replication and protein production in more advanced cell culture
models of HBV (Bloom et al., 2013; Chen et al., 2013). We have also
used anti-HBV ZFNs delivered with adeno-associated virus (AAV)
vectors to knock down viral replication in HBV-containing cell
lines. However, our data suggest that the cccDNA form may be
more resistant to DNA cleavage than plasmid or replicative DNA
forms, possibly because of chromatinization of cccDNA (Weber
et al., unpublished data). Thus studies using these enzymes against
HBV must carefully evaluate cleavage of cccDNA if they are to be
relevant to future curative approaches.
HSV has also been successfully targeted with HEs in vitro
(Grosse et al., 2011). Expression of an HSV-1-speciﬁc HE resulted
in both the inhibition of HSV-1 infection at low MOI and the
appearance of mutations at the target site in a model of active HSV
infection. More recently, Aubert et al. have demonstrated that HE
delivery with an AAV vector in an in vitro HSV latency model
functioned to decrease virus production following reactivation
of HSV (Aubert et al., in press). In this study, co-expression of
the end-processing 30-exonuclease, Trex2, together with an HE
increased the frequency of mutations at the target site. Further-
more, the virus genome appears to be more susceptible to
endonuclease-induced mutagenesis during virus reactivation and
genome replication compared to the latent form. Much like HBV,
the latent HSV genome is associated with histones bearing
modiﬁcations characteristic of transcriptionally inactive DNA or
heterochromatin, which can confer a compact structure to the
DNA. The use of histone deacetylase inhibitors to relax hetero-
chromatin and provide more access for the HE to target the HSV
DNA resulted in higher rates of mutagenesis at the target sites,
consistent with the notion that repressive chromatin can affect
mutagenesis (Aubert et al., in press).
In vivo results
Before DNA cleavage enzymes can be used against viruses in a
clinical setting, rigorous studies need to be performed in relevant
animal models. Recent work using DNA cleavage enzymes in
in vivo model systems has begun to provide initial evidence for
efﬁcacy. Following the anti-HBV effects seen by TALENs in vitro,
Bloom et al. demonstrated similar antiviral activity of the enzymes
in a murine hydrodynamic injection-based model of HBV infec-
tion. Tail vein injection of plasmids expressing TALENs targeted to
several open reading frames of the HBV genome, together with a
plasmid containing the HBV genome, caused mutations in the
cognate sites and knockdown of viral DNA and protein expression
in the mouse liver without evidence of toxicity (Bloom et al.,
2013). Using the same in vivo model, interferon-alpha (IFN-alpha)
was observed to enhance the antiviral effect of TALENs in a
synergistic manner (Chen et al., 2013). However, it is important
to note that this mouse model does not reproduce actual HBV
replication, and it does not contain cccDNA. Furthermore, hydro-
dynamic injection is not feasible as a delivery option for clinical
use. Thus, advances in both the animal model and method of
delivery will be required to continue to develop this approach.
There is also strong in vivo evidence for applying engineered
ZFNs to treat HTLV-1 infection. Tanaka et al. used a murine model
of adult T-cell leukemia (ATL) to demonstrate reduction in HTLV-1-
associated tumors after treatment with ZFNs in vivo (Tanaka et al.,
2013). Small animal models have also been utilized to test the
efﬁcacy of engineered DNA targeting enzymes against HIV. Nota-
bly, the HIV Tre-recombinase that induced proviral excision of HIV
in vitro also showed signiﬁcant antiviral effects in humanized
Rag2 / γc / mice that were engrafted with Tre-recombinase-
expressing primary CD4þ T cells or hematopoietic stem cells (HSC)
upon viral challenge (Hauber et al., 2013).
Pursuing further in vivo results
Relevance to human disease
The successes of these recent studies suggest that DNA cleavage
enzymes can be a viable and effective strategy for targeting viral
infections. The next step in the development of these therapeutic
strategies is to conduct comprehensive in vivo studies in appro-
priate animal models for each virus. Natural viral infections are
complex and multidimensional, and animal models provide better
means to evaluate experimental therapies in a setting closer to the
natural context of the infectious disease. It is essential to carefully
consider the animal model used and interpret the results knowing
the limitations inherent in each model. Additionally, the poten-
tially long life span of an animal allows possible evaluation of the
long-term impact of antiviral therapy on the pathogenesis of viral
infection and evaluation of any potential toxicity.
In terms of targeting viruses with DNA cleavage enzymes,
in vivo animal models may be useful to study:
 Biodistribution. To analyze delivery methods for reaching the
infected cells and the anatomical locations of persistent viral
infections.
 Dosing. How the body metabolizes a therapeutic drug candi-
date cannot be studied in cell culture. Animal models can
reveal essential information on the pharmacodynamic and
pharmacokinetic characteristics of antiviral treatments as well
as necessary therapeutic concentrations to achieve an effect.
 Viral latency. Animal models provide a more biologically rele-
vant system for the evaluation of viral genome accessibility
during latency or persistence. Several features of viral latency
are best studied with animals, including cryptic viral reservoirs
and epigenetic DNA modiﬁcations.
 Immune responses. Delivery vectors and the enzymes them-
selves can elicit an immune response upon inoculation, which
does not occur in vitro and thus can only be studied using
animal models. These studies can be limited by the need to use
immunodeﬁcient animals to accept transplants of human cells
in order to support infection with human-tropic viruses.
 Viral replication. Many viruses do not achieve full replication
cycles in cell culture models. Animal models, in many cases, can
offer better systems to analyze aspects of the complete viral life
cycle, including the generation of various viral DNA forms that
may not exist in cell culture. However, animal models may not
mimic all the aspects of viral replication that occur during
human infection, and it is important to recognize such
limitations.
Limitations of animal studies
Animal models are intended to reproduce the etiology and
pathology of human disease. Rodents and non-human primates
have been largely employed to test antiviral therapies including
drugs and vaccines. The use of large animals is expensive and
raises ethical concerns. As a consequence, limited numbers of
animals are typically available for studies, leading to high varia-
bility between animals and limited reproducibility. Small animal
models therefore are usually more useful.
Although some human pathogens can be used in animal
models, the pathogenesis of many viral infections may not be
exactly reproduced. For certain human-tropic viruses, the infection
can only be studied using the animal virus counterpart and its
natural host. Such animal viruses often differ signiﬁcantly from
their human-speciﬁc counterparts in many ways, including the
viral genome sequence. For antiviral DNA cleavage enzymes, in
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such cases separate enzymes need to be designed to target the
homologous sequence in the animal virus. Many of these difﬁcul-
ties can be addressed through the creation of humanized animals
(animals harboring certain human cell types or tissues). While
such animal models support infection with human pathogens,
they may present other technical challenges and have higher costs.
Finally, the immune responses generated in nonhuman mam-
malian species can differ from the human counterpart, either
because the immune system is different in the animal or the route
of infection is different. Such considerations need to be taken into
account when evaluating the potential immunogenicity of the
delivery vehicle and antiviral agent.
HBV animal models
Modeling HBV infection in vivo has proved challenging since
the only immunocompetent host beyond humans in which HBV
can fully replicate, the chimpanzee, is now banned for use in the
European Union and is discouraged for use in the US (Wadman,
2011). Replication-competent animal models exist for the HBV-
related duck HBV and woodchuck HBV, but these viruses are
mainly useful to study the molecular biology of hepadnaviruses
and have limited utility for studies of human HBV disease. While
there is evidence that HBV can replicate inefﬁciently in the Asian
tree shrew (Walter et al., 1996), this model is not widely accessible
for research. Therefore, efforts to develop alternative and easily
accessible animal models in which HBV can fully replicate are
ongoing.
Although HBV does not naturally replicate in mice, transgenic
mice have been developed that contain the HBV viral genome.
Numerous HBV transgenic mouse strains are available (Dandri
et al., 2006), and have been used to demonstrate that HBV can
replicate in mice when cell entry is bypassed, and that HBV virions
produced in transgenic mice are fully infectious when introduced
into chimpanzees (Guidotti et al., 1995, 1999). Nevertheless, HBV
transgenic mice are of limited use for HBV cure studies as a full
replicative life cycle does not occur, and they do not produce HBV
cccDNA. cccDNA is the template for viral protein synthesis during
natural infection and the principle target for DNA cleavage
enzymes. Subsequently, several groups are now using mice with
chimeric livers that contain human hepatocytes to study HBV
infection, because HBV is able to establish a productive infection in
such mice. Both the uPA-SCID mouse (Dandri et al., 2001;
Meuleman et al., 2005; Tsuge et al., 2005) and the fumaryl
acetoacetate hydrolase deﬁcient (FAH-/-) mouse (Bissig et al.,
2010; He et al., 2010) have been used to develop chimeric human
livers and study HBV replication with substantial success. These
mice are now considered the gold standard for in vivo studies of
HBV and can be use to evaluate the efﬁcacy, toxicity and pharma-
cokinetics of HBV-speciﬁc enzymes. However, due to the immu-
nodeﬁciency required for the engraftment of human hepatocytes,
these mice cannot be used to study vector- or enzyme-induced
immune responses. Additional drawbacks of this model include
technical challenges that result in low throughput of chimeric
animal production and the variation in levels of human chimerism
achieved (Meuleman et al., 2005; Mercer et al., 2001). None-
theless, this small animal model of HBV replication should sub-
stantially facilitate efﬁcacy testing of newly designed DNA cleavage
enzymes against HBV.
HSV animal models
HSV host tropism is not highly restricted to humans, and
therefore many animal models have been used to study HSV
biology and to test potential antiviral therapies. Animal strain
and gender, and HSV strain dictate susceptibility to infection,
establishment of latency, and frequency of reactivation (Caspary
et al., 1980; Hill et al., 1987). Mice and rabbits have been the most
commonly used animal models for HSV infection. Mice have been
widely used, and numerous transgenic and inbred strains are
available. Latent infection can be established in the trigeminal
ganglia by ocular or snout infection with HSV-1, or in the dorsal
root ganglia by vaginal or food pad inoculation with HSV-2.
Spontaneous reactivation and recurrent disease typical of human
infection do not occur in mice. However, virus reactivation can be
triggered by various stressors such as UV exposure, hyperthermic
shock, or by mechanical stress on the cells (e.g., culture of ganglia
explants) (Laycock et al., 1991; Sawtell and Thompson, 1992b).
A rabbit model more closely mimics the primary infection, estab-
lishment of latency, and spontaneous sporadic reactivation seen
with human HSV-1 infection (Gebhardt et al., 1999; Nesburn et al.,
1972). Guinea pigs have also been used in the evaluation of
therapeutic vaccines against genital HSV-2 infection, and these
animals have many clinical and pathologic features of acute and
recurrent genital disease similar to those seen in human infection
(Scriba, 1981; Scriba and Tatzber, 1981).
HIV animal models
Most in vivo work for HIV therapies has been performed with
non-human primates, but developing a small animal model for
HIV infection has been of high priority in the ﬁeld of HIV research.
As with mouse models for HBV, the ability to infect a mouse with
human-tropic HIV has been achieved through transgenics and
transplantation with human cells. These complex models are not
trivial to generate, and although they may support infection with
HIV, there are still fundamental differences from the human
infection and pathology. For testing HIV-targeted DNA cleavage
enzymes, the most important factors are successfully being able to
infect human T cells with HIV in the mouse and the establishment
of latent infection in resting T cells.
The best options for a humanized mouse model to study HIV
infection are based on transgenic immunodeﬁcient mice trans-
planted with either human hematapoietic stem cells (the NSG
mouse) or with human fetal liver, thymus and hematapoietic stem
cells (the bone marrow, liver, thymus (BLT) mouse) (reviewed in
Akkina (2013) and Denton and Garcia (2011)). The main difference
between these two models is that the BLT mouse contains a
human thymic microenvironment in which human T cells can
develop. The immune reconstitution of the gastrointestinal tract
and reproductive tract in the BLT mouse provide a more relevant
model for human HIV infection, especially in regards to HIV
mucosal transmission (Stoddart et al., 2011) and the establishment
of latently infected reservoirs (Marsden et al., 2012; Denton et al.,
2012). Both mouse models, despite their complexities, offer
simpler and substantially less expensive options than studies with
non-human primates. Limitations with mouse models include
differences from humans in delivery strategies, the requirement
for a facility that can handle immunodeﬁcient mice before
transplantation, and ethical and other issues resulting from the
requirement for human fetal tissue. Overall, the BLT mouse offers a
feasible model for studying HIV in the context of a functional
human immune system, although no animal model can fully
recapitulate the complexities of human HIV infection.
HPV animal models
HPV is highly restricted to humans and does not infect other
hosts, and thus studies in animal models will generally require
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using animal papillomaviruses (PVs). Several animal papilloma-
viruses have been studied to gain insight into the biology of viral
infection and associated diseases, and as models of human HPV
infection and carcinogenesis. The most commonly used models
include bovine papillomavirus (BPV), canine oral papillomavirus
(COPV), and cottontail rabbit papillomavirus (CRPV) (Campo,
2002). The CRPV model is a simple system for latent papilloma-
virus infection that can be established by using either domestic
or cottontail rabbits. CRPV infection of either rabbit species
can persist as benign lesions, can regress spontaneously, or can
progress to invasive metastatic carcinomas (Kreider and Bartlett,
1981; Rous and Beard, 1935). However, animal PV models have
important limitations, including different epithelial sites of infec-
tion, the large size of the animal hosts, their high cost, and
restricted availability of reagents. Recently, the laboratory mouse
papillomavirus (MusPV1) has been characterized, which can cause
disease in immunodeﬁcient nude mice, potentially providing a
small and more cost effective animal model using widely available
reagents (Ingle et al., 2011; Joh et al., 2012).
Challenges of enzyme delivery
A robust delivery system is critical if DNA cleavage enzymes are
to be effective against viral infections. A wide range of possible
delivery methods have been developed, and extensively reviewed
elsewhere, including both viral and non-viral delivery systems.
Generally, non-viral delivery systems induce weaker immune
responses but have shown poorer transduction efﬁciencies in vivo.
In contrast, viral vectors can achieve high delivery efﬁciency levels
but can potentially cause greater immunogenicity and even toxicity.
Thus, safety issues will be a major concern in any animal studies, as
discussed below.
The choice of optimal vehicle and route of delivery to achieve
expression of the enzyme(s) in the desired target cells and organs
will be dictated by the biology of the virus being targeted and the
nature of the animal model for each infection. Factors that must be
considered include the anatomical site(s) and accessibility of viral
reservoirs, the infected cell type, and the dosing necessary to
achieve the level of delivery required for therapeutic efﬁcacy.
Furthermore, the choice of delivery system will be inﬂuenced by
the speciﬁc type of DNA cleavage enzyme used. For example some
viral vectors, such as AAV, which have limited packaging capacity,
will not be feasible for larger enzymes such as TALENs or CRISPRs.
Additionally, the existence of a high number of near-identical
repeats in the coding sequence of modular enzymes (ZFNs and
TALENs) may promote recombination and genome instability
during production of viral vectors (Holkers et al., 2013).
Targeting hepatotropic viruses
As the site of HBV replication, the liver represents a major
potential target for novel DNA cleavage enzyme therapy. In
chronically infected individuals, HBV is largely restricted to hepa-
tocytes within the highly vascularized liver making the task of
delivery for an antiviral HBV therapy much easier than for other
persistent viral infections. Drugs or therapies can easily be
delivered systemically to the liver by intravenous or direct intra-
portal injections. Hepatocytes have proved highly susceptible to
transduction by a number of viral vectors (Fig. 2). Advanced
studies have shown that both adenovirus and AAV vectors can
be used to transduce the liver with high efﬁciency in vivo in animal
studies (Jaffe et al., 1992; Li et al., 1993; Nathwani et al., 2006) and
in clinical trials (Raper et al., 2002; Nathwani et al., 2011). No
signiﬁcant side effects have been reported in clinical trials for AAV.
On the other hand, a fatal adverse event was seen upon high dose
administration of adenovirus, thus necessitating severe caution in
future intravenous applications (Raper et al., 2003). Ultimately, if
safety and toxicity issues can be addressed sufﬁciently it could be
possible to efﬁciently transduce liver with an antiviral HBV-
speciﬁc DNA cleavage enzyme.
Targeting neurotropic viruses
HSV-1, HSV-2 and Varicella Zoster Virus (VZV) are human
neurotropic alphaherpesviruses. After the initial acute infection,
they establish a latent infection in cell bodies of sensory neurons
of the peripheral nervous system, typically the trigeminal ganglia
(HSV-1, VZV) and dorsal root ganglia (HSV-2, VZV), from which
they can later reactivate. Therefore, delivery strategies will need to
transduce peripheral neurons. In immunocompetent individuals,
latent HSV-1 exists in only 2–10% of sensory neurons in the
trigeminal ganglia (Wang et al., 2005). The number of HSV genome
copies is modest (2–50 copies/cell for HSV-1) in most infected
neurons (Wang et al., 2005, 2007). In mice, the viral burden as
deﬁned by HSV copy number and the number of infected cells
appears to be linked to the rate of recurrence (Wang et al., 2007;
Hoshino et al., 2007). Therefore, even incomplete inactivation of
latent genomes within infected neurons may signiﬁcantly reduce
disease severity and viral shedding, or even lead to the cure of HSV
infection.
The anatomical location of trigeminal and dorsal root ganglia
precludes the use of direct delivery methods in order to avoid
potentially severe complications. Therefore, alternative indirect
methods of gene delivery will be needed. Using neurotropic viral
vectors, it may be possible for delivery vectors to reach neuronal
cell bodies within the trigeminal and dorsal root ganglia via
projecting nerve axons. Studies in animals suggest that trigeminal
ganglia can be infected or transduced with viruses via the eye or
snout (Sawtell and Thompson, 1992a), whereas the dorsal root
ganglia can be infected or transduced with viruses via the footpad
(Liu et al., 2008) or vagina (Dutton et al., 2013). Furthermore, a
number of studies have suggested that AAV, adenovirus and
lentivirus vectors can all be used to efﬁciently transduce periph-
eral neurons in vivo (Glatzel et al., 2000; Terashima et al., 2009;
Mason et al., 2010; Yu et al., 2011). Taken together these observa-
tions suggest that safe and efﬁcient delivery of DNA cleavage
enzymes against latent neurotropic alphaherpesviruses may be
possible.
Targeting leukotropic viruses
Many viruses have developed mechanisms to hijack cells of the
immune system as sanctuary sites where they can evade the host
immune response and establish a latent infection. This makes their
treatment difﬁcult due to widespread distribution of infected cells
in distinct “reservoir” sites throughout the body. The challenge in
targeting these viruses with DNA cleavage enzymes is twofold.
First, the delivery system needs to efﬁciently transduce the
infected cell population, which is often inﬂuenced by both the
proliferative capacity of the cell type and the activation state.
Second, the delivery system must also be able to access the target
cell population throughout the body. Such a delivery systemwould
likely need to be delivered systemically in the blood and not be
limited by the presence of potential anatomical barriers. Different
viruses infect different kinds of immune cells, so the challenges of
transduction and access will vary for different antiviral therapies.
For example, Epstein Barr Virus (EBV) latency is established in B
lymphocytes (Klein et al., 2007), which are found throughout the
body in organs including blood and spleen; cytomegalovirus
(CMV) and HIV can establish latency in myeloid cells such as
monocytes and macrophages (Sinclair, 2008), which are found in
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organs such as bone marrow and blood; while HTLV (Lairmore
et al., 2011) and HIV (Chun et al., 1997; Chomont et al., 2009; Finzi
et al., 1997; Wong et al., 1997) establish latency in T lymphocyte
populations including resting memory CD4þ T cells, which can be
found in multiple anatomical sites including blood, lymph nodes,
and other lymphoid tissues, enabling the virus to establish lifelong
infection (Finzi et al., 1999; Siliciano et al., 2003; Strain et al.,
2003). Other hematopoietic cell types including progenitor cells
(Carter et al., 2010) and macrophages/microglia within the brain
(Thompson et al., 2011; Clements et al., 2002) have also been
implicated in HIV latency, further complicating delivery of HIV-
directed enzyme therapies. To date, a number of delivery systems
have shown promise for the transduction of different human
leukocyte cell populations, including adenovirus vectors (Knaan-
Shanzer et al., 2001; Maier et al., 2013; Schroers et al., 2004), AAV
vectors (Fig. 2, (Moreau et al., 2009; Pandya et al., 2013; Veldwijk
et al., 2010)), and lentivirus vectors (reviewed in (Frecha et al.,
2010)). Ultimately, any leukotropic virus therapy, whether using
viral or non-viral delivery vectors, will need to reach the entire
pool of latently infected cells, a highly challenging task.
Targeting latent virus within epithelium
Epithelium can be a site for active replication of viruses or a site
for latent viral infection. This is the case for HPV, for which
infection and replication is limited to basal cells of stratiﬁed
mucosal or cutaneous epithelium, and where the virus can estab-
lish latent infection (Doorbar, 2013; Broker et al., 2001). As a
double-stranded DNA virus, HPV is a potential target for DNA
cleavage enzyme-based therapies. Given the high incidence of
HPV-associated cancers, including cervical cancer, ano-genital
cancers, non-melanoma skin cancer, and head and neck tumors
(Harwood et al., 2004), antiviral therapies that target cells latently
infected with HPV are now being investigated.
As a target site for antiviral HPV gene therapy, the epithelium
presents both opportunities and challenges for gene delivery.
Treatment of HPV infections with visible lesions should be
relatively easy due to the need for only localized enzyme delivery
at the site of the lesion. Unfortunately, the site of latent HPV
infection is often not apparent, so a delivery method may need to
be applied broadly over a large area such as the cervical mucosa,
and may need to penetrate several layers of epithelium to reach
the latently infected reservoir. This presents a much more sig-
niﬁcant challenge and will likely need a delivery system that can
transduce the entire potential target cell population upon
either systemic (intravenous) or topical (cutaneous or mucosal)
delivery. A number of viral vectors (including AAV, Fig. 2 and
(Agrawal et al., 2004); adenovirus (Hirsch et al., 2006); and
lentivirus (Gagnoux-Palacios et al., 2005)) and non-viral delivery
systems (reviewed in (Branski et al., 2007)) have shown great
promise for gene delivery to human epithelium, although further
research is needed to determine whether these systems can be
Fig. 1. In vivo models for human persistent viral infections that are candidates for DNA cleavage enzyme therapy.
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used to efﬁciently deliver antiviral therapeutics to sites of latent
HPV infection in vivo.
Safety
One of the main reasons for carrying out in vivo studies is to
address questions surrounding safety. The major safety issues
around targeting viral infections with DNA cleavage enzymes have
to do with off-target cleavage, safety issues with the delivery
method and transgene expression, toxicity within targeted cells,
immunogenicity, and the potential for genomic insertion of
linearized episomal viral DNA.
Maximal speciﬁcity in recognizing and cleaving the correct
target DNA sequence is of fundamental importance in developing
a robust therapeutic strategy based on DNA cleavage enzymes.
Unintended cleavage of other sequences, or off-target cleavage,
can be detrimental, since repeated cleavage of nonspeciﬁc DNA
can lead to cytotoxicity and an increased likelihood of oncogenic
mutations. Modular DNA cleavage enzymes such as ZFNs and
TALENs are fairly straightforward to design to recognize a parti-
cular target sequence. However, individual units of the modular
DNA recognizing domains are not absolutely speciﬁc for a given
nucleotide (for TALENs) (Streubel et al., 2012) or nucleotide triplet
(for ZFNs) (Segal et al., 1999), therefore the speciﬁcity of an
enzyme can vary considerably depending on target sequence and
length. Substantial efforts have been made to improve speciﬁcity
and decrease off-target cleavage. For example, new FokI nuclease
domains have been designed that exert catalytic activity only upon
heterodimerization of two distinct nuclease halves, thus eliminat-
ing potential off-target cleavage sites caused by homodimerization
(Miller et al., 2007; Sollu et al., 2010; Szczepek et al., 2007). Certain
chimeric enzymes exhibit improved enzyme speciﬁcity, including
TALE/HE (Beurdeley et al., 2013; Boissel et al., 2013) and HE/
restriction enzyme (Fonfara et al., 2012) chimeras. By replacing the
FokI nuclease with a nuclease requiring DNA recognition such as
an HE, off-target cleavage can be reduced. In addition to improved
speciﬁcity, another advantage of these chimeric enzymes is that
they function as monomeric single-polypeptides, thus requiring
delivery of one individual transgene domain rather than two, as is
the case for ZFNs and TALENs. Mino et al. successfully targeted
HPV-18 with an individual ZFN-based monomer enzyme contain-
ing a staphylococcal nuclease, which does not require dimerization
(Mino et al., 2013). For the CRISPR/Cas-9 platform, it appears that
off-target cleavage is best prevented by target site selection, guide
RNA structure modiﬁcations, and utilizing DNA-nicking enzymes
instead of DSB-inducing enzymes (Cho et al., 2013; Mali et al.,
2013; Ran et al., 2013).
Once DNA cleavage enzymes are optimized, it is essential to
experimentally demonstrate minimal or undetectable levels of off-
target cleavage. For example, obligate-heterodimer FokI variants
were shown to cause reduced genome-wide cleavage events as
seen by a reduction of proteins that migrate to sites of DNA
damage (Miller et al., 2007; Szczepek et al., 2007). Cradick et al.
used a bioinformatics-based search tool to identify potential off-
target sites that were subsequently evaluated by mutation detec-
tion and sequencing, thus allowing reliable quantiﬁcation of off-
target cleavage (Cradick et al., 2013). Next generation sequencing
methods allow increased numbers and quality of reads of off-
target sites, adding conﬁdence to results. We have utilized off-
target search tools to identify the most similar off-target
sequences for three HBV-speciﬁc ZFNs. Seven thousand three
hundred sixteen sequence reads of the seven most closely related
off-target sites revealed no instances of off-target mutagenesis
(Weber et al., unpublished data).
In addition to off-target cleavage, other causes of cytotoxicity
exist. Depending on the delivery vector utilized, vector-derived
toxicity can result from the expression of viral products, the
transgenes themselves, or immune responses. Adenovirus and
AAV vectors have been improved to achieve efﬁcient transgene
expression with minimal or undetectable toxicity or immunogeni-
city. Much of this work has focused on targeting speciﬁc cells or
organs by varying the viral capsid proteins (reviewed thoroughly
in (Mingozzi and High, 2013)). Therapy-induced immunogenicity
can best be analyzed through the use of animal models. However,
several of the model systems for human viruses require immuno-
deﬁcient animals, and thus the analysis of any potential immune
response to therapy is limited (Fig. 1). In such cases, additional
safety and immunogenicity studies must be performed in non-
immunodeﬁcient animals.
Unlike many other gene therapy applications, targeted gene
disruption approaches do not require the insertion of a transgene
Fig. 2. Targets for antiviral DNA cleavage enzyme therapy. DNA viruses can persist in cells of lymphoid, hepatic, neural or epithelial origin. Delivery to sites of viral
persistence can be achieved using viral vectors such as AAV and adenovirus.
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into the host genome. Thus, these strategies avoid many of the
safety concerns with gene replacement applications, such as
transgene insertion in the vicinity of oncogenes or tumor sup-
pressors. For example, two early gene therapy trials for SCID-X1
caused the development of leukemia in several trial participants
(Hacein-Bey-Abina et al., 2003; Howe et al., 2008). However, DNA
disruption, regardless of whether the targeted DNA is endogenous
or exogenous, raises the possibility of unfavorable outcomes.
Ideally, many of these concerns can be addressed with properly
designed animal testing. For example, several of the viruses that
are candidates for targeting with DNA cleavage enzymes exist as
episomal DNA forms, including HBV, HPV and HSV. Cleavage of
this circularized DNA could promote viral insertion into the host
genome, which has been associated with oncogenesis for HBV and
HPV. Oncogenesis could also result from enzyme-induced muta-
genesis of off-target sites. Appropriate animal models will allow
testing for viral integration in the host genome, lymphoprolifera-
tion, or other signs of cancinogenesis.
Conclusions
Persistent pathogenic human viruses are a continuing global health
problem. Because of the inaccessibility and high costs of many
palliative treatments and vaccines, as well as the need for extended
treatment, there is a great need for novel curative approaches. The
recent achievements in gene manipulation through the use of DNA
cleavage enzymes should encourage continued pursuit of targeted
gene disruption for persistent viral infections. Investigators are
researching various enzyme platforms, and many advancements have
already been made in targeting the DNA of several human viruses.
Despite the promise of this technology, many questions still remain
about its feasibility in humans. Concerns about safety must be
addressed through appropriately designed animal model studies.
Research on methods for delivering therapeutic enzymes to infected
cells must progress in parallel with developments in enzyme technol-
ogy. Off-target enzyme cleavage, cytotoxicity, and immunogenicity still
pose hurdles to be overcome. The existence of suitable small animal
models for human viral infections is important for progress to be
made in this ﬁeld, and the models will need to be continually
improved. By combining the investigative efforts of the distinct ﬁelds
of DNA cleavage enzymes, viral vector delivery and animal models for
human viral infections, we foresee the rapid advancement of this
technology toward clinical application.
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